•  
  •  
  •  
  •  

2026-07-24 13:01:36

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mphasis Reports 17.5% YoY Revenue Growth in Q1 FY27; Secures $461 Million in New Deal Wins Driven by AI Demand
  • Fractal Analytics Reports 20% Revenue Growth and 92% Surge in Net Income for Q1 FY27
  • Route Mobile Ltd Financial Results Reveal Strong Operational Top-Line Expansion for Q1 FY27 as Revenue Reaches ₹1,151.51 Crore
  • CyberTech Systems and Software Limited Reports Q1 FY27 Net Profit Up 16% YoY to ₹9.48 Crore as Operational Revenue Reaches ₹68.45 Crore
  • ACME Solar operationalizes 3.62 GWh Battery Energy Storage System projects in Rajasthan

Keywords Selected:  GMPInspection

Stock Report

  • Wanbury Limited gets 6 observations from USFDA after cGMP inspection at Tanuku facility
  • Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
  • GMP Inspection by Malta Medicines Authority at Alkem's manufacturing facility located at Daman, India
  • GMP Inspection by Ministry of Health, Armenia at Alkem's manufacturing facility located at Sikkim, India
  • Biocon Limited updates on GMP inspection by USFDA at its Cranbury, New Jersey facility
  • Tyche Industries Ltd completes GMP inspection by ANVISA
  • Concord Biotech Ltd successfully completes Russian GMP insepction at its API facility
  • EIR from USFDA, for Shilpa Medicare Ltd. Unit VI, Bengaluru.
  • Shilpa Pharma Lifesciences Limited, Unit-1, ANVISA Audit from Brazil
  • Sun Pharma gets 8 observations from USFDA for Halol facility
  • Piramal Pharma Ltd completes USFDA inspection of Aurora facility with Zero Form-483 observations
  • USFDA completes GMP inspection at Dr. Reddy's Laboratories Ltd's API Middleburgh facility
  • ANSM Inspection at Cenexi's Fontenay Manufacturing Facility
  • Torrent Pharmaceuticals Ltd receives Form 483 from USFDA for Formulation Facility
  • Shilpa Pharma Lifesciences Ltd's Unit 2, Raichur, Karnataka has cleared the COFEPRIS-Mexico GMP Inspection
  • USFDA completes cGMP inspection of Divi's Laboratories Limited's Unit 2
  • Cipla Limited's Kurkumbh facility gets VAI classification from USFDA
  • Shilpa Pharma Lifesciences Ltd, Unit 2, Raichur, Karnataka has cleared the ANVISA-Brazil GMP inspection
  • Torrent Pharmaceuticals Ltd gets Form 483 with 5 observations for Indrad facility
  • Dr. Reddy's Laboratories Limited gets Form 483 from USFDA with 4 observations for API facility
  • Ami Organics'Limited, Unit I, Sachin, Surat in Gujarat has cleared PMDA Japan, GMP Inspection
  • Everest Organics Ltd updates on USFDA inspection
  • U.S. FDA completes inspection of Lupin's Dabhasa Facility with No Observations
  • EDQM conducts GMP inspection of SMS Pharmaceuticals Ltd's API facility

Latest Post

  • Mphasis Reports 17.5% YoY Revenue Growth in Q1 FY27; Secures $461 Million in New Deal Wins Driven by AI Demand
  • Fractal Analytics Reports 20% Revenue Growth and 92% Surge in Net Income for Q1 FY27
  • Route Mobile Ltd Financial Results Reveal Strong Operational Top-Line Expansion for Q1 FY27 as Revenue Reaches ₹1,151.51 Crore
  • CyberTech Systems and Software Limited Reports Q1 FY27 Net Profit Up 16% YoY to ₹9.48 Crore as Operational Revenue Reaches ₹68.45 Crore
  • ACME Solar operationalizes 3.62 GWh Battery Energy Storage System projects in Rajasthan


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025